BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2018;15:753-64. [DOI: 10.1038/s41575-018-0045-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Kalia S, Nath P, Pathak M, Anand AC. Treatment of Muscle Cramps in Patients With Cirrhosis of Liver: A Systematic Review. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.10.147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Møller S, Kimer N, Barløse M, Bendtsen F. Pathophysiological-based treatments of complications of cirrhosis. Scand J Gastroenterol 2020;55:383-94. [PMID: 32233873 DOI: 10.1080/00365521.2020.1744709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Maraolo AE, Buonomo AR, Zappulo E, Scotto R, Pinchera B, Gentile I. Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. RRCT 2019;14:129-35. [DOI: 10.2174/1574887114666181204102516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zhou J, Chen S, Zhang L, Zhai Y. Successful treatment of acute-on-chronic liver failure secondary to alcoholic cirrhosis with glucocorticoids and albumin: a case report. Daru 2021. [PMID: 34817844 DOI: 10.1007/s40199-021-00420-w] [Reference Citation Analysis]
5 Zaccherini G, Tufoni M, Iannone G, Caraceni P. Management of Ascites in Patients with Cirrhosis: An Update. J Clin Med 2021;10:5226. [PMID: 34830508 DOI: 10.3390/jcm10225226] [Reference Citation Analysis]
6 Simonetti RG, Perricone G, Nikolova D, Bjelakovic G, Gluud C. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis. Cochrane Database Syst Rev 2019;6:CD004039. [PMID: 31251387 DOI: 10.1002/14651858.CD004039.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kojima Y, Tsuchiya A, Ogawa M, Nojiri S, Takeuchi S, Watanabe T, Nakajima K, Hara Y, Yamashita J, Kikuta J, Takamura M, Ishii M, Terai S. Mesenchymal stem cells cultured under hypoxic conditions had a greater therapeutic effect on mice with liver cirrhosis compared to those cultured under normal oxygen conditions. Regen Ther 2019;11:269-81. [PMID: 31667206 DOI: 10.1016/j.reth.2019.08.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
8 Tufoni M, Zaccherini G, Caraceni P. Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference. Ann Transl Med 2019;7:S201. [PMID: 31656780 DOI: 10.21037/atm.2019.07.16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhou J, Cui S, He Q, Guo Y, Pan X, Zhang P, Huang N, Ge C, Wang G, Gonzalez FJ, Wang H, Hao H. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. Nat Commun 2020;11:240. [PMID: 31932588 DOI: 10.1038/s41467-019-14138-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 9.5] [Reference Citation Analysis]
10 Maraolo AE, Scotto R, Zappulo E, Pinchera B, Schiano Moriello N, Nappa S, Buonomo AR, Gentile I. Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. Expert Rev Anti Infect Ther 2020;18:191-202. [PMID: 32011191 DOI: 10.1080/14787210.2020.1725473] [Reference Citation Analysis]
11 Tufoni M, Zaccherini G, Caraceni P, Bernardi M. Albumin: Indications in chronic liver disease. United European Gastroenterol J 2020;8:528-35. [PMID: 32213034 DOI: 10.1177/2050640620910339] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Engelmann C, Clària J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol 2021;75 Suppl 1:S49-66. [PMID: 34039492 DOI: 10.1016/j.jhep.2021.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Xu X, Tan J, Wang H, Zhao W, Qin B. Risk Stratification Score to Predict Readmission of Patients With Acute Decompensated Cirrhosis Within 90 Days. Front Med (Lausanne) 2021;8:646875. [PMID: 34136498 DOI: 10.3389/fmed.2021.646875] [Reference Citation Analysis]
14 Francis P, Forman L. HATs Off to Clot Blockers: A Potential New Role for Statins After Transplantation. Liver Transpl 2021;27:1375-7. [PMID: 34118130 DOI: 10.1002/lt.26210] [Reference Citation Analysis]
15 Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol 2021;75 Suppl 1:S118-34. [PMID: 34039483 DOI: 10.1016/j.jhep.2021.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Reference Citation Analysis]
17 Is B, Bombassaro IZ, Tovo CV, de Mattos ÂZ, Ahlert M, Chiesa T, de Mattos AA. Albumin in the management of hepatic encephalopathy: A systematic review and meta-analysis. Ann Hepatol 2021;26:100541. [PMID: 34600143 DOI: 10.1016/j.aohep.2021.100541] [Reference Citation Analysis]
18 Patel VC, Williams R. Antimicrobial resistance in chronic liver disease. Hepatol Int. 2020;14:24-34. [PMID: 31797303 DOI: 10.1007/s12072-019-10004-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
19 Giannini EG. Improving prognosis of patients with very early hepatocellular carcinoma: How far are we going? Dig Liver Dis 2021;53:143-5. [PMID: 33257141 DOI: 10.1016/j.dld.2020.11.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Vega-Magaña N, Galiana A, Jave-Suárez LF, Garcia-Benavides L, Del Toro-Arreola S, Andrade-Villanueva JF, González-Hernández LA, Cremades R, Aguilar-Lemarroy A, Flores-Miramontes MG, Haramati J, Meza-Arroyo J, Bueno-Topete MR. Microbiome alterations are related to an imbalance of immune response and bacterial translocation in BDL-rats. Iran J Basic Med Sci 2020;23:178-85. [PMID: 32405360 DOI: 10.22038/IJBMS.2019.36487.8753] [Reference Citation Analysis]
21 Bernardi M, Zaccherini G, Caraceni P. Pro: The Role of Albumin in Pre–Liver Transplant Management. Liver Transpl 2019;25:128-34. [DOI: 10.1002/lt.25356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhang YY, Meng ZJ. Definition and classification of acute-on-chronic liver diseases. World J Clin Cases 2022; 10(15): 4717-4725 [DOI: 10.12998/wjcc.v10.i15.4717] [Reference Citation Analysis]
23 Kaur H, Premkumar M. Diagnosis and Management of Cirrhotic Cardiomyopathy. Journal of Clinical and Experimental Hepatology 2022;12:186-99. [DOI: 10.1016/j.jceh.2021.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Lange NF, Graf V, Caussy C, Dufour JF. PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. Int J Mol Sci 2022;23:4305. [PMID: 35457120 DOI: 10.3390/ijms23084305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Jagdish RK, Maras JS, Sarin SK. Albumin in Advanced Liver Diseases: The Good and Bad of a Drug! Hepatology 2021;74:2848-62. [PMID: 33772846 DOI: 10.1002/hep.31836] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
26 D'Amico G, Bernardi M, Angeli P. TOWARDS A NEW DEFINITION OF DECOMPENSATED CIRRHOSIS. J Hepatol 2021:S0168-8278(21)00438-4. [PMID: 34157322 DOI: 10.1016/j.jhep.2021.06.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
27 Zaccherini G, Tufoni M, Bernardi M. Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature. Hepat Med 2020;12:153-72. [PMID: 33149707 DOI: 10.2147/HMER.S264231] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
28 Bañares R, Bernardi M. Long-term albumin administration in patients with decompensated cirrhosis. It is time for a reappraisal. Liver Int 2019;39:45-8. [DOI: 10.1111/liv.13996] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
29 Wang X, Wu B. Critical issues in the diagnosis and treatment of liver cirrhosis. Gastroenterol Rep (Oxf) 2019;7:227-30. [PMID: 31413829 DOI: 10.1093/gastro/goz024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Chen Z, Xie Y, Zhou F, Zhang B, Wu J, Yang L, Xu S, Stedtfeld R, Chen Q, Liu J, Zhang X, Xu H, Ren J. Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease. Front Microbiol 2020;11:383. [PMID: 32265857 DOI: 10.3389/fmicb.2020.00383] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
31 Valery PC, Bernardes CM, Mckillen B, Amarasena S, Stuart KA, Hartel G, Clark PJ, Skoien R, Rahman T, Horsfall L, Hayward K, Gupta R, Lee A, Pillay L, Powell EE. The Patient's Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age. Hepatol Commun 2021;5:891-905. [PMID: 34027276 DOI: 10.1002/hep4.1681] [Reference Citation Analysis]
32 Sandi BB, Leão GS, de Mattos AA, de Mattos ÂZ. Long-term albumin administration in patients with cirrhosis and ascites: A meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2021;36:609-17. [PMID: 32914468 DOI: 10.1111/jgh.15253] [Reference Citation Analysis]